ESTRO 2024 - Abstract Book

S679

Clinical - Breast

ESTRO 2024

Median duration of T-DXd was 16.6+/-10.4 months and mean duration of SG was 11.9 +/- 4.76 months. All patients treated for palliation of bone metastases (9, 39.1%) achieved pain relief (NRS pre 1.8; NRS post 0.4, p=.014)

Conclusion:

RT delivered during T-DXd and SG showed mild toxicity. Longer follow-up and larger number of patients and treatments are needed to better understand the safety profile of radiotherapy delivered concurrently with these two drugs.

Keywords: ADCs, radiotherapy, concomitant

2822

Digital Poster

clinical evaluation of a personalized DIBH approach utilizing a novel ultimate breath-hold mechanism

Siyong Kim, Lulin Yuan, Todd Adams

Virginia Commonwealth University, Radiation Oncology, Richmond, USA

Purpose/Objective:

Long-term follow-up studies showed the increased risk for cardiac morbidity and mortality associated with left sided breast RT due to heart dose exposure. Deep inhale Breath-hold (DIBH) treatment has shown to reduce cardiac and lung dose. It is a common belief that there are 2 breathing types, chest-breathing and belly-breathing depending on which muscle is primarily used, and DIBH has been practiced with either chest-breathing-based only or belly-breathing-based only. It is also considered that chest-DIBH is advantageous in separating the heart from the breast while belly-DIBH is superior for increasing lung volume. In our clinic, therefore, we developed a novel breath hold mechanism, ultimate-DIBH that utilizes both chest-muscle and belly-muscle to acquire both advantages, larger heart separation and lung volume. The effectiveness of ultimate-DIBH was retrospectively analyzed using data obtained in a personalized approach.

Material/Methods: